<SEC-DOCUMENT>0000899243-22-014797.txt : 20220414
<SEC-HEADER>0000899243-22-014797.hdr.sgml : 20220414
<ACCEPTANCE-DATETIME>20220414161513
ACCESSION NUMBER:		0000899243-22-014797
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220412
FILED AS OF DATE:		20220414
DATE AS OF CHANGE:		20220414

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Apeiron Investment Group Ltd.
		CENTRAL INDEX KEY:			0001845711
		STATE OF INCORPORATION:			O1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40493
		FILM NUMBER:		22827421

	BUSINESS ADDRESS:	
		STREET 1:		BLOCK A, APT.12
		STREET 2:		IL-PIAZZETTA, TOWER ROAD
		CITY:			SLIEMA
		STATE:			O1
		ZIP:			SLM1605
		BUSINESS PHONE:		44 7557 251 563

	MAIL ADDRESS:	
		STREET 1:		BLOCK A, APT.12
		STREET 2:		IL-PIAZZETTA, TOWER ROAD
		CITY:			SLIEMA
		STATE:			O1
		ZIP:			SLM1605

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Angermayer Christian
		CENTRAL INDEX KEY:			0001845872

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40493
		FILM NUMBER:		22827420

	MAIL ADDRESS:	
		STREET 1:		BLOCK A, APT.12
		STREET 2:		IL-PIAZZETTA, TOWER ROAD
		CITY:			SLIEMA
		STATE:			O1
		ZIP:			SLM1605

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATAI Life Sciences N.V.
		CENTRAL INDEX KEY:			0001840904
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		180 VARICK STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
		BUSINESS PHONE:		(617) 699-5876

	MAIL ADDRESS:	
		STREET 1:		180 VARICK STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATAI Life Sciences B.V.
		DATE OF NAME CHANGE:	20210115
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-04-12</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001840904</issuerCik>
        <issuerName>ATAI Life Sciences N.V.</issuerName>
        <issuerTradingSymbol>ATAI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001845711</rptOwnerCik>
            <rptOwnerName>Apeiron Investment Group Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>66 &amp; 67, BEATRICE, AMERY STREET</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>SLIEMA</rptOwnerCity>
            <rptOwnerState>O1</rptOwnerState>
            <rptOwnerZipCode>SLM1707</rptOwnerZipCode>
            <rptOwnerStateDescription>MALTA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001845872</rptOwnerCik>
            <rptOwnerName>Angermayer Christian</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>66 &amp; 67, BEATRICE, AMERY STREET</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>SLIEMA</rptOwnerCity>
            <rptOwnerState>O1</rptOwnerState>
            <rptOwnerZipCode>SLM1707</rptOwnerZipCode>
            <rptOwnerStateDescription>MALTA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2022-04-12</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>55197</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4.8836</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1353916</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Apeiron Presight Capital Fund II, L.P.</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.84 to $4.90 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>Apeiron Investment Group Ltd. By: /s/ Julien Hofer, Director</signatureName>
        <signatureDate>2022-04-14</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Christian Angermayer</signatureName>
        <signatureDate>2022-04-14</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
